Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
A hydantoin compound useful for the prevention or treatment of hyperproliferative diseases or disorders.
1. A compound having the formula
, or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or adjuvant.
3. A method for treating a hyperproliferative disorder comprising administering a compound of claim 1 , or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment, thereby treating the hyperproliferative disorder wherein the hyperproliferative disorder is prostrate cancer.
4. The method of claim 3 , wherein the compound or a pharmaceutically acceptable salt thereof, is administered at a dosage in the range of from 0.01 mg per kg body weight per day to 500 mg per kg body weight per day.
5. The method of claim 3 , wherein the compound, or a pharmaceutically acceptable salt thereof, is administered at a dosage in the range of from 0.1 mg per kg body weight per day to 200 mg per kg body weight per day.
6. The method of claim 3 , wherein the compound or a pharmaceutically acceptable salt thereof, is administered at a dosage in the range of from 1 mg per kg body weight per day to 50 mg per kg body weight per day.
7. The method of claim 3 , wherein the compound or a pharmaceutically acceptable salt thereof, is administered at a dosage of 10 mg per kg body weight per day.
8. The method of claim 3 , wherein the compound is administered by intravenous injection, by injection into tissue, intraperitoneally, orally, or nasally.
9. The method of claim 3 , wherein the compound has a form selected from the group consisting of a solution, dispersion, suspension, powder, capsule, tablet, pill, time release capsule, time release tablet, and time release pill.
10. The pharmaceutical composition of claim 2 , wherein the compound is
11. The pharmaceutical composition of claim 2 , wherein the compound is
12. The pharmaceutical composition of claim 2 , comprising a solution of dimethylsulfoxide and phosphate buffered saline solution.
13. The pharmaceutical composition of claim 2 , comprising polyethylene glycol.
14. The pharmaceutical composition of claim 2 , wherein the compound is at a concentration of 1.5 mg/mL.
15. The pharmaceutical composition of claim 2 , comprising a solution of dimethylsulfoxide, a carboxymethylcellulose, a polysorbate, and water.
16. The method of claim 3 , wherein the hyperproliferative disorder is hormone sensitive prostate cancer.
17. The method of claim 3 , wherein the hyperproliferative disorder is hormone refractory prostate cancer.
18. The method of claim 3 , wherein the compound has the formula:
19. The method of claim 3 , wherein the compound has the formula:
20. The compound of claim 1 , wherein the compound has the formula:
21. The pharmaceutically acceptable salt of a compound of claim 1 , wherein the compound has the formula:
22. The compound of claim 1 , wherein the compound has the formula:
23. The pharmaceutically acceptable salt of a compound of claim 1 , wherein the compound has the formula:
24. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
25. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent.
26. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant.
27. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is administered by intravenous injection, by injection into tissue, intraperitoneally, orally, or nasally.
28. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition has a form selected from the group consisting of a solution, dispersion, suspension, powder, capsule, tablet, pill, time release capsule, time release tablet, and time release pill.
29. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is a capsule and is administered orally, and wherein the compound is
30. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is a tablet and is administered orally, and wherein the compound is
31. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is a pill and is administered orally, and wherein the compound is